Evidence-based comparison of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors

Affiliations

Comment

Hirotaka Watada. J Diabetes Investig. 2020 Jan.

. 2020 Jan;11(1):17-19.

doi: 10.1111/jdi.13131. Epub 2019 Sep 17.

¹ Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

No abstract available

Comment on

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. Zelniker TA, et al. Circulation. 2019 Apr 23;139(17):2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868. Circulation. 2019. PMID: 30786725

1. The DCCT Research Group . The effect of intensive treatment of diabetes on the development of long‐term complications in insulin‐dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986. - PubMed
1. UK Prospective Diabetes Study (UKPDS) Group . Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853. - PubMed
1. Gaede P, Vedel P, Larsen N, et al Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–393. - PubMed
1. Ueki K, Sasako T, Okazaki Y, et al Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J‐DOIT3): an open‐label, randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5: 951–964. - PubMed
1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–2471. - PubMed